Newswise — MedMira, Inc. (MedMira) (TSXV: MIR) is expanding its Multiplo product line with the addition of three new multiplex tests that deliver instant, simultaneous, single-cartridge results for syphilis (TP), HIV, and hepatitis C. The new tests being added to the product range include Multiplo TP/nTP, which detects both active and historic syphilis infections, Multiplo TP/HIV/nTP, and Multiplo TP/HIV/HCV, which simultaneously detects syphilis, HIV and hepatitis C.
The full Multiplo line is now available in international markets with analysis of highly regulated markets, possibly including North America and Europe, underway. MedMira will showcase its full Multiplo line for the first time at the 2014 American Association for Clinical Chemistry (AACC) Annual Meeting & Clinical Lab Expo.
The new tests all deliver instant results for syphilis infection, a disease with an increasing global prevalence rate. Multiplo TP/nTP and Multiplo TP/HIV/nTP take testing a step further, providing comprehensive screening and confirmatory results for both present and past syphilis infections. Detecting the presence of both current and previous infections provides critical information to help healthcare providers in determining the right course of treatment for their patients.
“The creativity and innovation powered by our patented RVF Technology is limitless and this expansion of our Multiplo product range is a prime example of how the technology enables new rapid tests to fast track through discovery, design, and development to meet customer demands,” said Dr. Kevin Jones, Senior Director Sales & Marketing, MedMira. “The WHO has identified syphilis as a serious global healthcare issue and our Multiplo tests will prove invaluable in large scale testing programs targeting multiple diseases, especially prenatal maternal initiatives. Multiplo TP/HIV is currently under evaluation as part of the WHO prequalification program and we look forward to working with them to bring our newest Multiplo tests to screening programs around the world.”
The World Health Organization (WHO) estimates that there are more than 12 million new cases of adult syphilis each year, with an additional 500,000 cases affecting infants through maternal transmission. It is the mission of WHO, and many other healthcare initiatives, to decrease transmission of HIV and syphilis from mothers to their children. With prenatal diagnosis using Multiplo rapid tests, at risk pregnancies can be identified within two minutes, greatly reducing the risk of mother-to-child HIV and syphilis transmission.
MedMira at AACC
MedMira will debut its expanded Multiplo product line at booth #2143 during the AACC taking place in Chicago from July 29-31. The Company will also showcase its Multiplo TP/HIV and Multiplo HBc/HIV/HCV tests, which are slated for launch in the U.S. in 2015, as well as its Reveal® single marker rapid HIV test and Miriad™ research tools.
MedMira also invites conference attendees to join them for the following presentations:OEM Lecture Series – MedMira Rapid Vertical Flow Technology: An in-depth look at how RVF Technology works and how it can be used to produce multiplexed assaysDr. Kevin Jones, Senior Director of Sales & Marketing Wednesday, July 30, 2014, 11:30 am – 11:50 am“A Rapid and Effective Tool for Monitoring Monoclonal Antibody Production” Poster # A-325Tuesday, July 29, 2014, 9:30 am – 5:00 pm
About MedMiraMedMira is a leading developer and manufacturer of vertical flow rapid diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as HIV and hepatitis C in just three easy steps. The Company’s tests are sold under the Reveal, Multiplo™ and Miriad™ brands in global markets. Based on its patented Rapid Vertical Flow Technology™, MedMira’s rapid HIV test is the first one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.